Sibylle Haid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sibylle Haid has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Pietschmann
TWINCORE, Centre for Experimental and Clinical Infection Research A Joint Venture Between the Helmholtz Centre for Infection Research and the Hannover Medical School Hannover Germany
13 shared publications Bettina Wiegmann
Biomedical Research in Endstage and Obstructive Lung Disease Hannover, (BREATH), German Center for Lung Research (DZL), Germany
5 shared publications- Rolf Müller
Saarland University
5 shared publications - Thomas Friedrich Schulz
Institute of Virology, Hannover Medical School
4 shared publications Antonia P. Gunesch
Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, Hannover, Germany
3 shared publications- Antonia P. Gunesch
Institute for Experimental Virology Twincore – Centre for Experimental and Clinical Infection Research Feodor-Lynen-Str. 7 30625 Hannover Germany
3 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by American Society for Microbiology in Journal of Virology
- Vol. 100 (9)
Arp2/3 complex-dependent actin remodeling is required for efficient RSV uncoating in A549 cells
Productive human respiratory syncytial virus (RSV) cell entry requires coordinated interactions between viral proteins and host-cell factors at the plasma membrane-actin cortex interface. Branched actin networks remodel this interface, but their precise contribution to the early stages of RSV infection remains unclear. Here, we interfered with Arp2/3 complex-dependent actin filament branching by generating A549 cell lines disrupted for expression of the essential Arp2 subunit by CRISPR/Cas9. Permanent loss of Arp2 reduced the infection of the RSV long GFP reporter virus, as quantified over the first 24 h post-infection. Compromised infection efficiency in Arp2 knockout cells persisted at later time points, and also resulted in reduced syncytia formation. Arp2 re-expression restored Arp2/3 complex-dependent actin remodeling and rescued RSV infection in Arp2 KO cells. Notably, impaired RSV infection was not accompanied by obvious changes in viral host cell attachment. Moreover, photoactivated localization microscopy (PALM) studies revealed comparable receptor diffusion and clustering in cells stably expressing mEos3.2-tagged insulin-like growth factor I receptor (IGF1R). Although Arp2/3-deficient cells displayed fewer, albeit larger, macropinosomes compared with WT cells, no changes were observed for internalized RSV genome levels. In contrast, Arp2-deficient cells appeared suppressed in RSV-F mediated virus-like particle uncoating efficiency. Consequently, viral mRNA expression and the cellular type III interferon response were reduced. Together, these data reveal that Arp2/3 complex-dependent, branched actin networks contribute to the efficiency of RSV uncoating. IMPORTANCE: Human respiratory syncytial virus (RSV) is a major cause of severe respiratory disease. The infection initiates at the plasma membrane-actin cortex interface, yet the role of actin in productive RSV entry has remained unclear. Using CRISPR/Cas9 disruption of the essential Arp2/3 complex subunit Arp2 in A549 cells, we show that branched actin networks are required for efficient RSV infection. Despite actin network remodeling, photoactivated localization microscopy showed unchanged diffusion and clustering of the RSV receptor IGF1R. Although macropinocytosis was affected in Arp2-deficient cells, RSV attachment and internalization were not influenced. In contrast, a β-lactamase virus-like-particle-based assay revealed a defect in RSV-F-mediated uncoating, followed by reduced viral gene expression and a weaker type III interferon response. These findings define Arp2/3 complex-dependent branched actin networks as a host determinant of RSV-F-mediated uncoating and provide a practical approach to quantify uncoating without engineering the RSV genome.
- 22 September 2026
- Published by American Society for Microbiology in Journal of Virology
- Vol. 100 (9)
Open AccessArp2/3 complex-dependent actin remodeling is required for efficient RSV uncoating in A549 cells
Productive human respiratory syncytial virus (RSV) cell entry requires coordinated interactions between viral proteins and host-cell factors at the plasma membrane-actin cortex interface. Branched actin networks remodel this interface, but their precise contribution to the early stages of RSV infection remains unclear. Here, we interfered with Arp2/3 complex-dependent actin filament branching by generating A549 cell lines disrupted for expression of the essential Arp2 subunit by CRISPR/Cas9. Permanent loss of Arp2 reduced the infection of the RSV long GFP reporter virus, as quantified over the first 24 h post-infection. Compromised infection efficiency in Arp2 knockout cells persisted at later time points, and also resulted in reduced syncytia formation. Arp2 re-expression restored Arp2/3 complex-dependent actin remodeling and rescued RSV infection in Arp2 KO cells. Notably, impaired RSV infection was not accompanied by obvious changes in viral host cell attachment. Moreover, photoactivated localization microscopy (PALM) studies revealed comparable receptor diffusion and clustering in cells stably expressing mEos3.2-tagged insulin-like growth factor I receptor (IGF1R). Although Arp2/3-deficient cells displayed fewer, albeit larger, macropinosomes compared with WT cells, no changes were observed for internalized RSV genome levels. In contrast, Arp2-deficient cells appeared suppressed in RSV-F mediated virus-like particle uncoating efficiency. Consequently, viral mRNA expression and the cellular type III interferon response were reduced. Together, these data reveal that Arp2/3 complex-dependent, branched actin networks contribute to the efficiency of RSV uncoating. IMPORTANCE: Human respiratory syncytial virus (RSV) is a major cause of severe respiratory disease. The infection initiates at the plasma membrane-actin cortex interface, yet the role of actin in productive RSV entry has remained unclear. Using CRISPR/Cas9 disruption of the essential Arp2/3 complex subunit Arp2 in A549 cells, we show that branched actin networks are required for efficient RSV infection. Despite actin network remodeling, photoactivated localization microscopy showed unchanged diffusion and clustering of the RSV receptor IGF1R. Although macropinocytosis was affected in Arp2-deficient cells, RSV attachment and internalization were not influenced. In contrast, a β-lactamase virus-like-particle-based assay revealed a defect in RSV-F-mediated uncoating, followed by reduced viral gene expression and a weaker type III interferon response. These findings define Arp2/3 complex-dependent branched actin networks as a host determinant of RSV-F-mediated uncoating and provide a practical approach to quantify uncoating without engineering the RSV genome.
- Open Access
- 19 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (25) , eaed4499
Respiratory syncytial viral load drives ciliated cell dedifferentiation and suppresses antiviral immunity
Respiratory syncytial virus (RSV) causes severe lower respiratory disease, yet how it reshapes airway epithelial cells and evades innate immunity remains incompletely understood. We infected adult primary human airway epithelial cultures with RSV and analyzed infected and bystander cells over time using single-cell RNA sequencing and imaging. RSV mainly infected ciliated cells, triggering a virus load–dependent shutdown of genes involved in ciliogenesis, antigen presentation, and innate sensing, including key interferon (IFN) and pattern recognition pathways. Only a subset of infected cells produced type I and III IFNs, while bystander cells exhibited strong IFN-stimulated gene (ISG) signatures. Neither IFN treatment nor ISG induction eliminated infection, but IRF1, an antiviral transcription factor not suppressed by RSV, remained robustly expressed. Ectopic IRF1 expression in vitro reduced viral replication. These findings reveal how RSV evades antiviral defenses and highlight IRF1 as a potential target for therapeutic intervention.
- 19 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (25) , eaed4499
Open AccessRespiratory syncytial viral load drives ciliated cell dedifferentiation and suppresses antiviral immunity
Respiratory syncytial virus (RSV) causes severe lower respiratory disease, yet how it reshapes airway epithelial cells and evades innate immunity remains incompletely understood. We infected adult primary human airway epithelial cultures with RSV and analyzed infected and bystander cells over time using single-cell RNA sequencing and imaging. RSV mainly infected ciliated cells, triggering a virus load–dependent shutdown of genes involved in ciliogenesis, antigen presentation, and innate sensing, including key interferon (IFN) and pattern recognition pathways. Only a subset of infected cells produced type I and III IFNs, while bystander cells exhibited strong IFN-stimulated gene (ISG) signatures. Neither IFN treatment nor ISG induction eliminated infection, but IRF1, an antiviral transcription factor not suppressed by RSV, remained robustly expressed. Ectopic IRF1 expression in vitro reduced viral replication. These findings reveal how RSV evades antiviral defenses and highlight IRF1 as a potential target for therapeutic intervention.
- Open Access
Respiratory syncytial virus load-dependent ciliated cell dedifferentiation and downregulation of immune response genes
Respiratory syncytial virus (RSV) can cause severe lower respiratory tract infections in infants, older adults, and individuals with chronic or immunocompromising conditions. To understand how RSV affects airway cells, we infected primary human airway epithelial cultures with RSV and analyzed infected and bystander cells using time-resolved single-cell RNA sequencing and imaging. RSV mainly infected ciliated cells, triggering a virus load-dependent shutdown of genes involved in ciliogenesis, antigen presentation, and innate sensing, including key interferon (IFN) and pattern recognition pathways. Only a subset of infected cells produced type I and III IFNs, while bystander cells exhibited strong IFN-stimulated gene (ISG) signatures. Neither IFN treatment nor ISG induction eliminated infection, but IRF1, an antiviral transcription factor not suppressed by RSV, remained robustly expressed. Ectopic IRF1 expression in vitro reduced viral replication. These findings reveal how RSV evades antiviral defenses and highlight IRF1 as a potential target for therapeutic intervention.
Open AccessRespiratory syncytial virus load-dependent ciliated cell dedifferentiation and downregulation of immune response genes
Respiratory syncytial virus (RSV) can cause severe lower respiratory tract infections in infants, older adults, and individuals with chronic or immunocompromising conditions. To understand how RSV affects airway cells, we infected primary human airway epithelial cultures with RSV and analyzed infected and bystander cells using time-resolved single-cell RNA sequencing and imaging. RSV mainly infected ciliated cells, triggering a virus load-dependent shutdown of genes involved in ciliogenesis, antigen presentation, and innate sensing, including key interferon (IFN) and pattern recognition pathways. Only a subset of infected cells produced type I and III IFNs, while bystander cells exhibited strong IFN-stimulated gene (ISG) signatures. Neither IFN treatment nor ISG induction eliminated infection, but IRF1, an antiviral transcription factor not suppressed by RSV, remained robustly expressed. Ectopic IRF1 expression in vitro reduced viral replication. These findings reveal how RSV evades antiviral defenses and highlight IRF1 as a potential target for therapeutic intervention.
- Open Access
- 9 July 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (28)
Mycophenolic acid treatment drives the emergence of novel SARS-CoV-2 variants
Mycophenolic acid (MPA) is commonly used in immunosuppressive regimens following solid organ transplantation. We demonstrate that MPA treatment reproducibly inhibits the replication of a range of viruses, including severe respiratory syndrome coronavirus 2 (SARS-CoV-2). Mechanistically, we identified cellular guanosine triphosphate pool depletion as a key mediator of this antiviral effect. Strikingly, this inhibition can be overcome which was correlated with the emergence of three breakthrough mutations in the SARS-CoV-2 genome (S P812R, ORF3 Q185H, and E S6L). Subsequent analyses confirmed that the combination of these mutations conferred accelerated replication kinetics, higher viral titers, and more rapid onset of cytopathic effects, but not MPA resistance. Comparison of global transcriptional responses to infection highlighted dysregulation of specific cellular gene programs under MPA treatment prior to breakthrough mutation emergence. Together, these findings identify viral and host drivers of variant emergence under immunosuppression. They also advocate for close monitoring of immunosuppressed patients, where emergence of novel viral variants with a fitness advantage may arise.
- 9 July 2025
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 122 (28)
Open AccessMycophenolic acid treatment drives the emergence of novel SARS-CoV-2 variants
Mycophenolic acid (MPA) is commonly used in immunosuppressive regimens following solid organ transplantation. We demonstrate that MPA treatment reproducibly inhibits the replication of a range of viruses, including severe respiratory syndrome coronavirus 2 (SARS-CoV-2). Mechanistically, we identified cellular guanosine triphosphate pool depletion as a key mediator of this antiviral effect. Strikingly, this inhibition can be overcome which was correlated with the emergence of three breakthrough mutations in the SARS-CoV-2 genome (S P812R, ORF3 Q185H, and E S6L). Subsequent analyses confirmed that the combination of these mutations conferred accelerated replication kinetics, higher viral titers, and more rapid onset of cytopathic effects, but not MPA resistance. Comparison of global transcriptional responses to infection highlighted dysregulation of specific cellular gene programs under MPA treatment prior to breakthrough mutation emergence. Together, these findings identify viral and host drivers of variant emergence under immunosuppression. They also advocate for close monitoring of immunosuppressed patients, where emergence of novel viral variants with a fitness advantage may arise.
- Open Access
- 6 March 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (3) , e0121023
Repurposing screen identifies novel candidates for broad-spectrum coronavirus antivirals and druggable host targets
Libraries composed of licensed drugs represent a vast repertoire of molecules modulating physiological processes in humans, providing unique opportunities for the discovery of host-targeting antivirals. We screened the Repurposing, Focused Rescue, and Accelerated Medchem (ReFRAME) repurposing library with approximately 12,000 molecules for broad-spectrum coronavirus antivirals and discovered 134 compounds inhibiting an alphacoronavirus and mapping to 58 molecular target categories. Dominant targets included the 5-hydroxytryptamine receptor, the dopamine receptor, and cyclin-dependent kinases. Gene knock-out of the drugs’ host targets including cathepsin B and L (CTSB/L; VBY-825), the aryl hydrocarbon receptor (AHR; Phortress), the farnesyl-diphosphate farnesyltransferase 1 (FDFT1; P-3622), and the kelch-like ECH-associated protein 1 (KEAP1; Omaveloxolone), significantly modulated HCoV-229E infection, providing evidence that these compounds inhibited the virus through acting on their respective host targets. Counter-screening of all 134 primary compound candidates with SARS-CoV-2 and validation in primary cells identified Phortress, an AHR activating ligand, P-3622-targeting FDFT1, and Omaveloxolone, which activates the NFE2-like bZIP transcription factor 2 (NFE2L2) by liberating it from its endogenous inhibitor KEAP1, as antiviral candidates for both an Alpha - and a Betacoronavirus . This study provides an overview of HCoV-229E repurposing candidates and reveals novel potentially druggable viral host dependency factors hijacked by diverse coronaviruses.
- 6 March 2024
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 68 (3) , e0121023
Open AccessRepurposing screen identifies novel candidates for broad-spectrum coronavirus antivirals and druggable host targets
Libraries composed of licensed drugs represent a vast repertoire of molecules modulating physiological processes in humans, providing unique opportunities for the discovery of host-targeting antivirals. We screened the Repurposing, Focused Rescue, and Accelerated Medchem (ReFRAME) repurposing library with approximately 12,000 molecules for broad-spectrum coronavirus antivirals and discovered 134 compounds inhibiting an alphacoronavirus and mapping to 58 molecular target categories. Dominant targets included the 5-hydroxytryptamine receptor, the dopamine receptor, and cyclin-dependent kinases. Gene knock-out of the drugs’ host targets including cathepsin B and L (CTSB/L; VBY-825), the aryl hydrocarbon receptor (AHR; Phortress), the farnesyl-diphosphate farnesyltransferase 1 (FDFT1; P-3622), and the kelch-like ECH-associated protein 1 (KEAP1; Omaveloxolone), significantly modulated HCoV-229E infection, providing evidence that these compounds inhibited the virus through acting on their respective host targets. Counter-screening of all 134 primary compound candidates with SARS-CoV-2 and validation in primary cells identified Phortress, an AHR activating ligand, P-3622-targeting FDFT1, and Omaveloxolone, which activates the NFE2-like bZIP transcription factor 2 (NFE2L2) by liberating it from its endogenous inhibitor KEAP1, as antiviral candidates for both an Alpha - and a Betacoronavirus . This study provides an overview of HCoV-229E repurposing candidates and reveals novel potentially druggable viral host dependency factors hijacked by diverse coronaviruses.
- Open Access
- 8 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor
Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infection in infants, older adults and the immunocompromised. Effective directly acting antivirals are not yet available for clinical use. To address this, we screen the ReFRAME drug-repurposing library consisting of 12,000 small molecules against RSV. We identify 21 primary candidates including RSV F and N protein inhibitors, five HSP90 and four IMPDH inhibitors. We select lonafarnib, a licensed farnesyltransferase inhibitor, and phase III candidate for hepatitis delta virus (HDV) therapy, for further follow-up. Dose-response analyses and plaque assays confirm the antiviral activity (IC50: 10-118 nM). Passaging of RSV with lonafarnib selects for phenotypic resistance and fixation of mutations in the RSV fusion protein (T335I and T400A). Lentiviral pseudotypes programmed with variant RSV fusion proteins confirm that lonafarnib inhibits RSV cell entry and that these mutations confer lonafarnib resistance. Surface plasmon resonance reveals RSV fusion protein binding of lonafarnib and co-crystallography identifies the lonafarnib binding site within RSV F. Oral administration of lonafarnib dose-dependently reduces RSV virus load in a murine infection model using female mice. Collectively, this work provides an overview of RSV drug repurposing candidates and establishes lonafarnib as a bona fide fusion protein inhibitor.
- 8 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-15
Open AccessDrug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor
Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infection in infants, older adults and the immunocompromised. Effective directly acting antivirals are not yet available for clinical use. To address this, we screen the ReFRAME drug-repurposing library consisting of 12,000 small molecules against RSV. We identify 21 primary candidates including RSV F and N protein inhibitors, five HSP90 and four IMPDH inhibitors. We select lonafarnib, a licensed farnesyltransferase inhibitor, and phase III candidate for hepatitis delta virus (HDV) therapy, for further follow-up. Dose-response analyses and plaque assays confirm the antiviral activity (IC50: 10-118 nM). Passaging of RSV with lonafarnib selects for phenotypic resistance and fixation of mutations in the RSV fusion protein (T335I and T400A). Lentiviral pseudotypes programmed with variant RSV fusion proteins confirm that lonafarnib inhibits RSV cell entry and that these mutations confer lonafarnib resistance. Surface plasmon resonance reveals RSV fusion protein binding of lonafarnib and co-crystallography identifies the lonafarnib binding site within RSV F. Oral administration of lonafarnib dose-dependently reduces RSV virus load in a murine infection model using female mice. Collectively, this work provides an overview of RSV drug repurposing candidates and establishes lonafarnib as a bona fide fusion protein inhibitor.
- Open Access
- 4 January 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (6)
Persicamidine – Außergewöhnliche Sesquarterpenoide mit potenter antiviraler Bioaktivität gegen Coronaviren
Eine neue Substanzfamilie von ungewöhnlichen Sesquarterpenoiden (Persicamidine A–E) mit hoher antiviraler Aktivität wurde aus einem kürzlich entdeckten Aktinobakterien‐Stamm (Kibdelosporangium persicum sp. nov.) isoliert, welcher aus einem Wüstenhabitat im Iran stammt. Umfangreiche NMR‐Analysen entlarvten ein hexazyklisches Terpenoidmolekül mit einer modifizierten Zuckereinheit auf einer Seite und einer höchst ungewöhnlichen Isoharnstoffeinheit, die mit der Terpenoidstruktur verbunden ist. Die Strukturen der fünf Derivate unterschieden sich ausschließlich durch die Aminoalkyl‐Seitenkette, die an die Isoharnstoffeinheit gebunden ist. Die Persicamidine A–E zeigten eine starke Aktivität gegen hCoV‐229E‐ und SARS‐CoV‐2‐Viren im nanomolaren Bereich bei gleichzeitig sehr guten Selektivitätsindizes. Dies macht die Persicamidine zu vielversprechenden Ausgangsverbindungen für die Arzneimittelentwicklung.
- 4 January 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (6)
Open AccessPersicamidine – Außergewöhnliche Sesquarterpenoide mit potenter antiviraler Bioaktivität gegen Coronaviren
Eine neue Substanzfamilie von ungewöhnlichen Sesquarterpenoiden (Persicamidine A–E) mit hoher antiviraler Aktivität wurde aus einem kürzlich entdeckten Aktinobakterien‐Stamm (Kibdelosporangium persicum sp. nov.) isoliert, welcher aus einem Wüstenhabitat im Iran stammt. Umfangreiche NMR‐Analysen entlarvten ein hexazyklisches Terpenoidmolekül mit einer modifizierten Zuckereinheit auf einer Seite und einer höchst ungewöhnlichen Isoharnstoffeinheit, die mit der Terpenoidstruktur verbunden ist. Die Strukturen der fünf Derivate unterschieden sich ausschließlich durch die Aminoalkyl‐Seitenkette, die an die Isoharnstoffeinheit gebunden ist. Die Persicamidine A–E zeigten eine starke Aktivität gegen hCoV‐229E‐ und SARS‐CoV‐2‐Viren im nanomolaren Bereich bei gleichzeitig sehr guten Selektivitätsindizes. Dies macht die Persicamidine zu vielversprechenden Ausgangsverbindungen für die Arzneimittelentwicklung.
- Open Access
- 4 January 2023
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (6)
Persicamidines—Unprecedented Sesquarterpenoids with Potent Antiviral Bioactivity against Coronaviruses
A new family of highly unusual sesquarterpenoids (persicamidines A–E) exhibiting significant antiviral activity was isolated from a newly discovered actinobacterial strain, Kibdelosporangium persicum sp. nov., collected from a hot desert in Iran. Extensive NMR analysis unraveled a hexacyclic terpenoid molecule with a modified sugar moiety on one side and a highly unusual isourea moiety fused to the terpenoid structure. The structures of the five analogues differed only in the aminoalkyl side chain attached to the isourea moiety. Persicamidines A–E showed potent activity against hCoV‐229E and SARS‐CoV‐2 viruses in the nanomolar range together with very good selectivity indices, making persicamidines promising as starting points for drug development.
- 4 January 2023
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (6)
Open AccessPersicamidines—Unprecedented Sesquarterpenoids with Potent Antiviral Bioactivity against Coronaviruses
A new family of highly unusual sesquarterpenoids (persicamidines A–E) exhibiting significant antiviral activity was isolated from a newly discovered actinobacterial strain, Kibdelosporangium persicum sp. nov., collected from a hot desert in Iran. Extensive NMR analysis unraveled a hexacyclic terpenoid molecule with a modified sugar moiety on one side and a highly unusual isourea moiety fused to the terpenoid structure. The structures of the five analogues differed only in the aminoalkyl side chain attached to the isourea moiety. Persicamidines A–E showed potent activity against hCoV‐229E and SARS‐CoV‐2 viruses in the nanomolar range together with very good selectivity indices, making persicamidines promising as starting points for drug development.
- Open Access
- 29 November 2022
- Published by Wiley in Angewandte Chemie
- Vol. 134 (52)
Thiamyxine: Struktur und Biosynthese myxobakterieller RNA‐Virus Inhibitoren**
Unsere Suche nach neuen myxobakteriellen Naturstoffen führte zur Entdeckung der Thiamyxine, thiazol‐ und thiazolinreichen nichtribosomalen Peptid‐Polyketid‐Hybriden mit potenter antiviraler Aktivität. Vier Mitglieder dieser noch unbeschriebenen Naturstofffamilie wurden isoliert. Darunter auch ein offenkettiges Derivat, welches eine Glycerin‐Einheit am C‐Terminus trägt. Basierend auf der Analyse des Thiamyxin‐Biosythesegenclusters und unterstützt durch Fütterungsexperimente mit isotopenmarkierten Vorläufersubstanzen, beschreiben wir hier neben der Strukturaufklärung der Thiamyxine ein Biosynthesemodell. Als Besonderheit ist der Einbau eines 2‐(Hydroxymethyl)‐4‐methylpent‐3‐ensäure‐Bausteins durch die Polyketidsynthase zu nennen, die auch eine GCN5‐verwandte N‐Acetyltransferase‐Decarboxylase‐Domäne beinhaltet. Die Thiamyxine zeigen in mit Corona‐, Zika‐ und Dengue‐Virus infizierten Zellkulturmodellen eine deutliche Hemmung von RNA‐Viren. Ihre Potenz, bis zu einer halb‐maximalen Hemmkonzentration von 560 nM, in Verbindung mit milderen zytotoxischen Wirkungen auf menschliche Zelllinien, indizieren ein Potenzial für die weitere Entwicklung der Thiamyxine.
- 29 November 2022
- Published by Wiley in Angewandte Chemie
- Vol. 134 (52)
Open AccessThiamyxine: Struktur und Biosynthese myxobakterieller RNA‐Virus Inhibitoren**
Unsere Suche nach neuen myxobakteriellen Naturstoffen führte zur Entdeckung der Thiamyxine, thiazol‐ und thiazolinreichen nichtribosomalen Peptid‐Polyketid‐Hybriden mit potenter antiviraler Aktivität. Vier Mitglieder dieser noch unbeschriebenen Naturstofffamilie wurden isoliert. Darunter auch ein offenkettiges Derivat, welches eine Glycerin‐Einheit am C‐Terminus trägt. Basierend auf der Analyse des Thiamyxin‐Biosythesegenclusters und unterstützt durch Fütterungsexperimente mit isotopenmarkierten Vorläufersubstanzen, beschreiben wir hier neben der Strukturaufklärung der Thiamyxine ein Biosynthesemodell. Als Besonderheit ist der Einbau eines 2‐(Hydroxymethyl)‐4‐methylpent‐3‐ensäure‐Bausteins durch die Polyketidsynthase zu nennen, die auch eine GCN5‐verwandte N‐Acetyltransferase‐Decarboxylase‐Domäne beinhaltet. Die Thiamyxine zeigen in mit Corona‐, Zika‐ und Dengue‐Virus infizierten Zellkulturmodellen eine deutliche Hemmung von RNA‐Viren. Ihre Potenz, bis zu einer halb‐maximalen Hemmkonzentration von 560 nM, in Verbindung mit milderen zytotoxischen Wirkungen auf menschliche Zelllinien, indizieren ein Potenzial für die weitere Entwicklung der Thiamyxine.
- Open Access
- 28 November 2022
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 61 (52)
Thiamyxins: Structure and Biosynthesis of Myxobacterial RNA‐Virus Inhibitors**
During our search for novel myxobacterial natural products, we discovered the thiamyxins: thiazole‐ and thiazoline‐rich non‐ribosomal peptide‐polyketide hybrids with potent antiviral activity. We isolated four congeners of this unprecedented natural product family with the non‐cyclized thiamyxin D fused to a glycerol unit at the C‐terminus. Alongside their structure elucidation, we present a concise biosynthesis model based on biosynthetic gene cluster analysis and isotopically labelled precursor feeding. We report incorporation of a 2‐(hydroxymethyl)‐4‐methylpent‐3‐enoic acid moiety by a GCN5‐related N‐acetyltransferase‐like decarboxylase domain featuring polyketide synthase. The thiamyxins show potent inhibition of RNA viruses in cell culture models of corona, zika and dengue virus infection. Their potency up to a half maximal inhibitory concentration of 560 nM combined with milder cytotoxic effects on human cell lines indicate the potential for further development of the thiamyxins.
- 28 November 2022
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 61 (52)
Open AccessThiamyxins: Structure and Biosynthesis of Myxobacterial RNA‐Virus Inhibitors**
During our search for novel myxobacterial natural products, we discovered the thiamyxins: thiazole‐ and thiazoline‐rich non‐ribosomal peptide‐polyketide hybrids with potent antiviral activity. We isolated four congeners of this unprecedented natural product family with the non‐cyclized thiamyxin D fused to a glycerol unit at the C‐terminus. Alongside their structure elucidation, we present a concise biosynthesis model based on biosynthetic gene cluster analysis and isotopically labelled precursor feeding. We report incorporation of a 2‐(hydroxymethyl)‐4‐methylpent‐3‐enoic acid moiety by a GCN5‐related N‐acetyltransferase‐like decarboxylase domain featuring polyketide synthase. The thiamyxins show potent inhibition of RNA viruses in cell culture models of corona, zika and dengue virus infection. Their potency up to a half maximal inhibitory concentration of 560 nM combined with milder cytotoxic effects on human cell lines indicate the potential for further development of the thiamyxins.